DK2931294T3 - Forbinding med føtale fibroblaster og føtale keratinocytter - Google Patents
Forbinding med føtale fibroblaster og føtale keratinocytter Download PDFInfo
- Publication number
- DK2931294T3 DK2931294T3 DK13803032.5T DK13803032T DK2931294T3 DK 2931294 T3 DK2931294 T3 DK 2931294T3 DK 13803032 T DK13803032 T DK 13803032T DK 2931294 T3 DK2931294 T3 DK 2931294T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- foetal
- keratinocytes
- fibroblasts
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Sammensætning, som omfatter en blanding af humane føtale keratinocyt-celler og humane føtale fibroblastiske celler, hvor forholdet mellem keratino-cytcellerne og de fibroblastiske celler ligger mellem 0,75 og 2,5.
2. Sammensætning ifølge krav 1, hvor forholdet er 1:1 eller 7:3.
3. Sammensætning ifølge krav 1 eller 2, hvor blandingen af celler er integreret i en ikke-immunogen extracellulær matrice.
4. Sammensætning ifølge krav 3, kendetegnet ved, at den indeholder mellem 0,1 og 5,106 celler per mL eller cm3 af matricen.
5. Sammensætning ifølge krav 3 eller 4, kendetegnet ved, at matricen indeholder mindst én forbindelse, der er udvalgt fra gruppen bestående af: kollagen, fibronektin, fibrin, elastin og blandinger deraf.
6. Sammensætning ifølge krav 3 eller 4, hvor matricen består af human fibrinogen, human faktor XIII, human fibronektin, plasminogen, bovin aprotinin og human thrombin.
7. Forbinding, som indeholder sammensætningen sådan som defineret i et hvilket som helst af kravene 1 til 6.
8. Forbinding ifølge krav 7, kendetegnet ved, at den er steril og emballeret i en beholder, der er uigennemtrængelig for mikroorganismer.
9. Sammensætning sådan som defineret ifølge et af kravene 1 til 6 til anvendelse som lægemiddel.
10. Sammensætning sådan som defineret ifølge et af kravene 1 til 6 til anvendelse i behandlingen af alle hudmangler, for eksempel et sår, en forbrænding eller ulcus.
11. Fremgangsmåde til fremstilling af en sammensætning sådan som defineret i kravene 1 til 6, som omfatter et trin med blanding af humane føtale kera-tinocytceller og humane føtale fibroblastiske celler i en ikke-immunogen ext-racellulær matrice i et forhold, som ligger mellem 0,75 og 2,5.
12. Fremgangsmåde til fremstilling ifølge krav 11, kendetegnet ved, at forholdet er 1:1 eller 7:3.
13. Fremgangsmåde til fremstilling ifølge krav 11 eller 12, kendetegnet ved, at den inden blandingstrinnet omfatter de to følgende trin: a) opnåelse af humane føtale keratinocytceller, og b) opnåelse af humane føtale fibroblastiske celler.
14. Fremgangsmåde til fremstilling ifølge krav 11 eller 12, kendetegnet ved, at den inden blandingstrinnet omfatter de to følgende trin: a) opnåelse af en bank af humane føtale keratinocytceller, og b) opnåelse af en bank af humane føtale fibroblastiske celler.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1261953A FR2999083B1 (fr) | 2012-12-12 | 2012-12-12 | Pansement contenant des fibroblastes et des keratinocytes foetaux |
PCT/EP2013/076438 WO2014090961A1 (fr) | 2012-12-12 | 2013-12-12 | Pansement contenant des fibroblastes et des keratinocytes foetaux |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2931294T3 true DK2931294T3 (da) | 2017-03-13 |
Family
ID=47989106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13803032.5T DK2931294T3 (da) | 2012-12-12 | 2013-12-12 | Forbinding med føtale fibroblaster og føtale keratinocytter |
Country Status (7)
Country | Link |
---|---|
US (1) | US11351201B2 (da) |
EP (1) | EP2931294B1 (da) |
JP (1) | JP6391587B2 (da) |
CA (1) | CA2894811C (da) |
DK (1) | DK2931294T3 (da) |
FR (1) | FR2999083B1 (da) |
WO (1) | WO2014090961A1 (da) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1281870B1 (it) | 1995-04-27 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Pelle artificiale umana costituita da materiali biocompatibili a base di derivati dell'acido ialuronico |
US6673603B2 (en) * | 2000-09-01 | 2004-01-06 | Modex Therapeutiques, S.A. | Cell paste comprising keratinocytes and fibroblasts |
US7144729B2 (en) | 2000-09-01 | 2006-12-05 | Dfb Pharmaceuticals, Inc. | Methods and compositions for tissue regeneration |
US8394371B2 (en) * | 2002-02-11 | 2013-03-12 | Neocutis Sa | Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
EP1718317A1 (en) * | 2004-02-13 | 2006-11-08 | Intercytex Limited | Wound healing profile |
WO2012038923A1 (en) * | 2010-09-22 | 2012-03-29 | Centre Hospitalier Universitaire Vaudois | Anti-fibrotic response provided by fetal cells to implants and delivery systems |
-
2012
- 2012-12-12 FR FR1261953A patent/FR2999083B1/fr active Active
-
2013
- 2013-12-12 WO PCT/EP2013/076438 patent/WO2014090961A1/fr active Application Filing
- 2013-12-12 JP JP2015547032A patent/JP6391587B2/ja active Active
- 2013-12-12 US US14/651,887 patent/US11351201B2/en active Active
- 2013-12-12 EP EP13803032.5A patent/EP2931294B1/fr active Active
- 2013-12-12 CA CA2894811A patent/CA2894811C/fr active Active
- 2013-12-12 DK DK13803032.5T patent/DK2931294T3/da active
Also Published As
Publication number | Publication date |
---|---|
JP2016504313A (ja) | 2016-02-12 |
EP2931294A1 (fr) | 2015-10-21 |
CA2894811C (fr) | 2023-08-29 |
FR2999083B1 (fr) | 2015-01-23 |
CA2894811A1 (fr) | 2014-06-19 |
WO2014090961A1 (fr) | 2014-06-19 |
US11351201B2 (en) | 2022-06-07 |
FR2999083A1 (fr) | 2014-06-13 |
US20150320804A1 (en) | 2015-11-12 |
JP6391587B2 (ja) | 2018-09-19 |
EP2931294B1 (fr) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shpichka et al. | Skin tissue regeneration for burn injury | |
Shevchenko et al. | A review of tissue-engineered skin bioconstructs available for skin reconstruction | |
KR101495281B1 (ko) | 피부 재생 또는 상처 치유를 위한 중간엽 줄기세포-하이드로겔-생분해성 또는 중간엽 줄기세포-하이드로겔-비분해성 지지체 조성물 | |
Ruszczak | Effect of collagen matrices on dermal wound healing | |
AU2018226406B2 (en) | Tissue graft | |
Cerqueira et al. | Human skin cell fractions fail to self-organize within a gellan gum/hyaluronic acid matrix but positively influence early wound healing | |
JP7303612B2 (ja) | 熱傷の進行の緩和ならびに皮膚移植片の取り込みおよび治癒の改善における再生細胞の使用 | |
US10149924B1 (en) | Ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof | |
Gangwar et al. | Bioengineered acellular dermal matrix for the repair of full thickness skin wounds in rats | |
Klama-Baryła et al. | Autologous and allogeneic skin cell grafts in the treatment of severely burned patients: retrospective clinical study | |
Zhang et al. | PDGF-BB/SA/Dex injectable hydrogels accelerate BMSC-mediated functional full thickness skin wound repair by promoting angiogenesis | |
Shen et al. | Bilayer silk fibroin/sodium alginate scaffold promotes vascularization and advances inflammation stage in full-thickness wound | |
US20220280693A1 (en) | Tissue derived porous matrices and methods for making and using same | |
DK2931294T3 (da) | Forbinding med føtale fibroblaster og føtale keratinocytter | |
US20150328268A1 (en) | Marine Plants Extract for Wound Healing | |
Altmeyer et al. | Wound healing and skin physiology | |
Hasan et al. | Bovine reticulum derived extracellular matrix (b-REM) for reconstruction of full thickness skin wounds in rats | |
Arribas-Arribas et al. | Nanostructured fibrin-agarose hydrogels loaded with allogeneic fibroblasts as bio-dressings for acute treatment of massive burns | |
Han | Cell Therapy | |
Segreto | The use of the" stem graft" in chronic wounds: in vitro analysis, clinical and comparative study | |
Wang et al. | Recent advances in the adjunctive management of diabetic foot ulcer: Focus on noninvasive technologies | |
JP2023516693A (ja) | 予め血管新生された真皮-表皮組織を得るための方法 | |
Alharbi | Preserved extracellular matrix in non-enzymatically detached cultured keratinocyte sheets bolsters the healing effects on grafted burn wounds | |
Jorgensen et al. | 10 Controlled Therapeutic | |
TR2024002381A2 (tr) | Di̇yabeti̇k hastaliğindan müzdari̇p ki̇şi̇ler i̇çi̇n tam yaralarin i̇yi̇leşti̇ri̇lmesi̇ne olanak sağlayan bi̇r kompozi̇syon |